🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 52 of 173

  1. US 10620204

    Antibody-mediated neutralization of Ebola viruses

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10611998

    Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10612045

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10611880

    Oxime cross-linked biocompatible polymer hydrogels and methods of use thereof

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10611851

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10610583

    Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10610492

    Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10610493

    Detoxification using nanoparticles

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10610535

    Diarylpropionitrile therapy for treatment of multiple sclerosis

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10610601

    Polymeric antibiotics

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10604806

    Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10604501

    Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10604492

    CFTR regulators and methods of use thereof

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10604493

    Compositions, methods of use, and methods of treatment

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10603356

    Compositions and method for treatment of inflammatory bowel disease

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10603311

    Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10604585

    Modulation of PTPRA to treat arthritis

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10603390

    Real-time feedback system control technology platform with dynamically changing stimulations

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10596125

    Nanowire-coated microdevice and method of making and using the same

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10597340

    Synthesis of fluorinated radiopharmaceuticals via electrochemical fluorination

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10597455

    Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10596245

    Staphylococcus aureus materials and methods

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10597680

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10598665

    Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10596259

    Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10596247

    Methods and compositions for attenuated chlamydia as vaccine and vector

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10588897

    Piericidin bacterial inhibitors

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10590137

    Mercaptopurine hemihydrate

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10591471

    Suppression of SPLA2-integrin binding for treating an inflammatory condition or suppressing cell proliferation

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10588982

    Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10590155

    Mitochondria-targeting fluorescent potassium+ sensor and method of making the same

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10588911

    Compositions comprising triterpenoids

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10590182

    Binding-triggered transcriptional switches and methods of use thereof

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10590171

    Exosomes and methods of making and using the same

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10591468

    Circulating antibodies against MAA adducts as biomarker for coronary artery disease

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10588867

    Modulating antibacterial immunity via bacterial membrane-coated nanoparticles

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10589003

    Methods for coating surfaces with antimicrobial agents

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10589250

    Automated purification and formulation device for radiopharmaceutical compounds

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10590142

    Deuterated amlexanox

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10588907

    Methods and compositions for inhibiting the interaction of menin with MLL proteins

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10583180

    Method for treating adenosine deaminase severe combined imunodeficiency

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10583202

    Homologous recombination in multipotent adult progenitor cells

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10583145

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10583186

    Compositions comprising recombinant probiotic bacteria and methods of use thereof

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10583134

    Methods and therapeutic combinations for treating tumors

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10584313

    Method of producing a differentiated mammalian cell comprising culturing a single mammalian blastomere

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10584105

    Immunoproteasome inhibitor analogs

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10584306

    Surfactant microemulsions

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.